James Wilson, WuXi Global Forum at JPM20

FDA puts up a red light for Pas­sage Bio’s first gene ther­a­py pro­gram, de­lay­ing a pro­gram from James Wilson's group at Penn

Gene ther­a­py pi­o­neer James Wil­son spear­head­ed an­i­mal stud­ies demon­strat­ing the po­ten­tial of new treat­ments in­ject­ed di­rect­ly in­to the brain, look­ing to jump­start a once-and-done fix for an ex­tra­or­di­nar­i­ly rare dis­ease called GM1 gan­gliosi­do­sis in in­fants. His team at the Uni­ver­si­ty of Penn­syl­va­nia pub­lished their work on mon­keys and hand­ed it over to Pas­sage Bio, a Wil­son-in­spired start­up build­ing a pipeline of gene ther­a­pies — with an IND for PBGM01 to lead the way.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA